Adherence to Ocular Hypotensive Medication in Patients With Primary Open Angle Glaucoma in Ghana.
Journal
Journal of glaucoma
ISSN: 1536-481X
Titre abrégé: J Glaucoma
Pays: United States
ID NLM: 9300903
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
received:
03
08
2022
accepted:
23
03
2023
medline:
31
8
2023
pubmed:
20
4
2023
entrez:
20
04
2023
Statut:
ppublish
Résumé
There is a high rate of nonadherence to ocular hypotensive medications in a highly prevalent glaucoma setting, which warrants the attention of caregivers so as to inform their discussion of the possible barriers to adherence with their patients. To assess adherence to ocular hypotensive medication objectively among glaucoma patients in Ghana and to identify factors associated with adherence. The prospective, observational cohort study included consecutive patients with primary open angle glaucoma treated with Timolol at the Christian Eye Centre, Cape Coast, Ghana. Adherence was assessed using Medication Event Monitoring System (MEMS) for a period of 3 months. MEMS adherence was defined as the number of doses taken divided by the number of doses prescribed, expressed in percent. Patients with adherence of 75% or less were classified as nonadherent. Associations with glaucoma medication self-efficacy, eyedrop-taking behaviors, and health beliefs were also assessed. Of the 139 patients (mean age, 65 y [SD, 13 y]) included in the study, 107 (77.0%) were nonadherent when assessed with MEMS, compared with only 47 (33.8%) who self-reported being nonadherent. Overall, mean adherence was 48.5%±29.7. In univariate analysis, MEMS adherence was significantly associated with educational level ( χ2 =9.18, P =0.01) and the number of systemic comorbidities ( χ2 =6.03, P =0.049). Overall, mean adherence was low, and adherence was associated with educational level and number of systemic comorbidities in univariate analysis.
Identifiants
pubmed: 37079490
doi: 10.1097/IJG.0000000000002227
pii: 00061198-990000000-00206
doi:
Substances chimiques
Antihypertensive Agents
0
Ophthalmic Solutions
0
Types de publication
Observational Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
777-782Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure: L.R. is a scientific advisor for Olleyes, Inc. The remaining authors declare no conflict of interest.
Références
Blindness GBD. Vision Impairment C, Vision Loss Expert Group of the Global Burden of Disease S. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021;9:e144–e160.
Zhang N, Wang J, Li Y, et al. Prevalence of primary open angle glaucoma in the last 20 years: a meta-analysis and systematic review. Sci Rep. 2021;11:13762.
Kyari F, Abdull MM, Bastawrous A, et al. Epidemiology of glaucoma in sub-saharan Africa: prevalence, incidence and risk factors. Middle East Afr J Ophthalmol. 2013;20:111–125.
Budenz DL, Barton K, Whiteside-de Vos J, et al. Prevalence of glaucoma in an urban West African population: the Tema Eye Survey. JAMA Ophthalmol. 2013;131:651–658.
Ntim-Amponsah CT, Amoaku WM, Ofosu-Amaah S, et al. Prevalence of glaucoma in an African population. Eye (Lond). 2004;18:491–497.
Mwanza JC, Tulenko SE, Barton K, et al. Eight-year incidence of open-angle glaucoma in the tema eye survey. Ophthalmology. 2019;126:372–380.
Mwanza JC, Tulenko SE, Budenz DL, et al. Incidence of glaucoma progression and rate of visual field deterioration in a cohort of urban Ghanaians. J Glaucoma. 2022;31:503–510.
Miglior S, Zeyen T, Pfeiffer N, et al. Results of the European glaucoma prevention study. Ophthalmology. 2005;112:366–375.
Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–713; discussion 829-730.
Boland MV, Chang DS, Frazier T, et al. Electronic monitoring to assess adherence with once-daily glaucoma medications and risk factors for nonadherence: the automated dosing reminder study. JAMA Ophthalmol. 2014;132:838–844.
Newman-Casey PA, Niziol LM, Gillespie BW, et al. The association between medication adherence and visual field progression in the collaborative initial glaucoma treatment study. Ophthalmology. 2020;127:477–483.
Olthoff CM, Schouten JS, Van de Borne BW, et al. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology. 2005;112:953–961.
Mehari T, Giorgis AT, Shibeshi W. Level of adherence to ocular hypotensive agents and its determinant factors among glaucoma patients in Menelik II Referral Hospital, Ethiopia. BMC Ophthalmol. 2016;16:131.
Tamrat L, Gessesse GW, Gelaw Y. Adherence to topical glaucoma medications in Ethiopian patients. Middle East Afr J Ophthalmol. 2015;22:59–63.
Tadesse F, Mulugeta A. Compliance to topical anti-glaucoma medication among glaucoma patients at Menelik II Tertiary Hospital, Addis Ababa, Ethiopia. Ethiop J Health Dev. 2015;29:31–36.
Anbesse DH, Yibekal BT, Assefa NL. Adherence to topical glaucoma medications and associated factors in Gondar University Hospital Tertiary Eye Care Center, northwest Ethiopia. Eur J Ophthalmol. 2019;29:189–195.
Ocansey S, Kyei S, Diafo A, et al. Cost of the medical management and prescription pattern for primary open-angle glaucoma (POAG) in Ghana-a retrospective cross-sectional study from three referral facilities. BMC Health Serv Res. 2016;16:282.
Santos MA, Ayena DK, Kuaovi KR, et al. [Compliance with medical treatment in primary open-angle glaucoma in Lome]. J Fr Ophtalmol. 2016;39:459–466.
Tchabi S, Abouki C, Sounouvou I, et al. [Survey of medical treatment in primary open-angle glaucoma]. J Fr Ophtalmol. 2011;34:624–628.
Murdoch I, Nyakundi D, Baker H, et al. Adherence with medical therapy for primary open-angle glaucoma in Kenya - A Pilot Study. Patient Prefer Adherence. 2020;14:221–225.
Alan LR, Kelly WM. Medication adherence in patients with ocular hypertension or glaucoma. Expert Rev Ophthalmol. 2019;14:199–210.
Zaharia AC, Dumitrescu OM, Radu M, et al. Adherence to therapy in glaucoma treatment-a review. J Pers Med. 2022;12:514.
Koffuor GA, Ababio-Danso B, Gyanfosu L, et al. The efficacy of NHIS-listed anti-glaucoma drugs in the management of primary open-angle glaucoma. J Med Biomed Sci. 2012;2:50–58.
Robin AL, Novack GD, Covert DW, et al. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol. 2007;144:533–540.
Sayner R, Carpenter DM, Blalock SJ, et al. Accuracy of patient-reported adherence to glaucoma medications on a visual Analog Scale compared with electronic monitors. Clin Ther. 2015;37:1975–1985.
Racette L, Abu SL, Poleon S, et al. The Impact of the coronavirus disease 2019 pandemic on adherence to ocular hypotensive medication in patients with primary open-angle glaucoma. Ophthalmology. 2022;129:258–266.
Foster PJ, Buhrmann R, Quigley HA, et al. The definition and classification of glaucoma in prevalence surveys. Br J Ophthalmol. 2002;86:238–242.
Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73:691–705.
Rees G, Leong O, Crowston JG, et al. Intentional and unintentional nonadherence to ocular hypotensive treatment in patients with glaucoma. Ophthalmology. 2010;117:903–908.
Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67–74.
Sleath B, Blalock SJ, Robin A, et al. Development of an instrument to measure glaucoma medication self-efficacy and outcome expectations. Eye (Lond). 2010;24:624–631.
Sleath B, Blalock SJ, Stone JL, et al. Validation of a short version of the glaucoma medication self-efficacy questionnaire. Br J Ophthalmol. 2012;96:258–262.
Broadbent E, Petrie KJ, Main J, et al. The brief illness perception questionnaire. J Psychosom Res. 2006;60:631–637.
Friedman DS, Okeke CO, Jampel HD, et al. Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma. Ophthalmology. 2009;116:1097–1105.
Okeke CO, Quigley HA, Jampel HD, et al. Adherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid study. Ophthalmology. 2009;116:191–199.
Van Buskirk EM. The compliance factor. Am J Ophthalmol. 1986;101:609–610.
Winfield AJ, Jessiman D, Williams A, et al. A study of the causes of non-compliance by patients prescribed eyedrops. Br J Ophthalmol. 1990;74:477–480.
Kass MA, Gordon M, Meltzer DW. Can ophthalmologists correctly identify patients defaulting from pilocarpine therapy? Am J Ophthalmol. 1986;101:524–530.
Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet. 2019;393:1505–1516.
Christensen A, Osterberg LG, Hansen EH. Electronic monitoring of patient adherence to oral antihypertensive medical treatment: a systematic review. J Hypertens. 2009;27:1540–1551.
Hahn SR, Friedman DS, Quigley HA, et al. Effect of patient-centered communication training on discussion and detection of nonadherence in glaucoma. Ophthalmololgy. 2010;117:1339.e6–1347.e6.